Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
VION PHARMACEUTICALS INC (VION)
|
Add to portfolio |
|
|
|
| Price: |
$0.75
| | Metrics |
| OS: |
8.04
|
M
| |
|
|
| Market cap: |
$6.03
|
M
| |
|
|
|
Net debt:
|
$36.1
|
M
| |
|
|
|
EV:
|
$42.1
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($19.4)
|
M
| |
|
|
|
EBIT
|
($19.8)
|
M
| |
|
|
| EPS |
$3,102.60
| |
0.0
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 | Dec-31-01 |
| Revenues | 0.0 | 0.1 | 0.0 | 0.0 | 0.3 | 0.4 | 0.2 | 0.7 |
| Revenue growth | -34.8% | 200.0% | -4.3% | -91.6% | -26.7% | 57.6% | -63.4% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.1 | 0.0 | 0.0 | 0.3 | 0.4 | 0.2 | 0.7 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 7.6 | 8.4 | 5.8 | 3.2 | | | | |
| Research and development | 8.0 | 10.6 | 8.4 | 6.6 | 4.4 | 4.0 | 5.7 | 8.6 |
| General and administrative | | | | | 3.0 | 2.6 | 2.7 | 3.1 |
| EBIT | -25.1 | -32.6 | -27.2 | -19.8 | -16.5 | -11.9 | -13.0 | -15.0 |
| EBIT margin | -58355.8% | -49334.8% | -123859.1% | -86178.3% | -6000.4% | -3179.5% | -5471.0% | -2309.8% |
| Pre-tax income | -30.1 | -34.3 | -25.3 | -18.0 | -16.0 | -11.8 | -12.5 | -13.8 |
| Income taxes | -0.3 | -0.3 | 0.0 | 0.0 | 0.0 | 0.0 | -0.2 | 0.0 |
| Tax rate | 0.9% | 1.0% | | | | | 1.8% | 0.0% |
| Net income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net margin | -69.4% | -51.5% | -115.2% | -78.4% | -5.8% | -3.2% | -5.2% | -2.1% |
| |
| Diluted EPS | ($4.04) | ($5.05) | ($3.83) | ($2.77) | ($0.30) | ($0.36) | ($0.43) | ($0.51) |
| Shares outstanding (diluted) | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|